* Resverlogix Corp(RVXCF) - ? entered into a Right of First Refusal Agreement with Hepalink USA Inc?
* Resverlogix Corp(RVXCF) - ?Hepalink USA paid $8 million to Resverlogix(RVXCF) in consideration for right of first refusal granted?
* Resverlogix(RVXCF) - ?during first 60 day period, deal may only be terminated upon mutual agreement; thereafter, agreement may be terminated by either party?
* Resverlogix-Hepalink USA granted Right of First Refusal in connection with licensing of right to develop, among others, products having RVX-208 in U.S.
* Resverlogix-Hepalink USA granted Right of First Refusal related to licensing of right to develop products with RVX-208 in U.S. until April 15, 2019? Source text for Eikon: Further company coverage:
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM